Program
ABBV-8736
A development code.
In AbbVie's pipeline, TREM1
. Its studies are mostly in Crohn Disease, led by AbbVie.
Furthest: phase 2, since Aug 8, 20243 company-led studies, 1 open or runningNext primary completion: Jan 2030 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 31 open or running | phase 2since Aug 8, 2024 | Aug 8, 2024 | Jan 2030phase 2 · NCT06548542 |
- Named in AbbVie’s own pipeline as
ABBV-8736
, phase 2, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 8, 2024First study: phase 2 study in Crohn DiseaseFirst studyNCT06548542 · 590 planned · United States, Austria, Belgium and more
- Aug 19, 2025Phase 1 study in Healthy VolunteerNCT07141199 · 24 enrolled · United States
- Feb 10, 2026Phase 1 study in Healthy VolunteerNCT07413133 · 40 enrolled · United States
Ahead
- Jan 2030Primary completion: phase 2 study in Crohn DiseaseNCT06548542
TargetBeta
“TREM1”the company's pipeline, read by Claude · source
Other programs on TREM1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| BI 3032950 | Boehringer Ingelheim | phase 2 | 3 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07413133Healthy Volunteer · United States | 1 | Completed | Jun 19, 2026 | 40 |
| NCT07141199Healthy Volunteer · United States | 1 | Completed | Mar 23, 2026 | 24 |
| NCT06548542Crohn Disease · United States, Austria, Belgium and more | 2 | Recruiting | Jan 2030 | 590 |
How it is read
Names in the registry
- “ABBV-8736”, 4 entries
Codes read as this program: ABBV8736.
Conditions, from the studies’ own filings
- Crohn Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.